WO2004103371A1 - Use of cftr inhibitors for the treatment of chemotherapy-induced diarrhea - Google Patents
Use of cftr inhibitors for the treatment of chemotherapy-induced diarrhea Download PDFInfo
- Publication number
- WO2004103371A1 WO2004103371A1 PCT/IB2004/001660 IB2004001660W WO2004103371A1 WO 2004103371 A1 WO2004103371 A1 WO 2004103371A1 IB 2004001660 W IB2004001660 W IB 2004001660W WO 2004103371 A1 WO2004103371 A1 WO 2004103371A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chemotherapeutic agent
- patient
- diarrhea
- diarrheagenic
- irinotecan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Definitions
- the present invention relates to the treatment of diarrhea induced by pharmacologically active agents, in particular chemotherapeutic agents.
- Chemotherapy-induced diarrhea is a prevalent and severe toxicity associated with a variety of sole agents and combinations chemotherapy regimens used for the treatment of cancer. Not only does the occurrence of diarrhea reduce the quality of life of cancer patients, it may also strongly impact the clinical decision about chemotherapy regimens so that patients may undergo changes in treatments. These changes include dose reductions, delays in administration of subsequent drug cycles, and a total discontinuation of therapy. Acute or persistent diarrhea can often increase the cost of care when conventional treatment is unsuccessful and hospitalization is required. Some chemotherapeutic drugs are more likely than others to cause diarrhea. Cisplatin and 5-fluorouracil, when administered alone, commonly cause diarrhea, as does irinotecan.
- diarrhea can be classified as osmotic, secretory, exudative, postresection, and motor. Osmotic diarrhea results from the ingestion of poorly absorbed substances that retard fluid absorption.
- cystic fibrosis transmembrane conductance regulator a member of the ATP-binding Cassette (ABC), subfamily C member 7 (ABCC7) is the final common pathway for intestinal chloride (Cl " ) and thus fluid secretion into the lumen of the small and large intestine.
- CFTR cystic fibrosis transmembrane conductance regulator
- ABSC ATP-binding Cassette
- ABCC7 subfamily C member 7
- EID enterotoxin-induced diarrhea
- second messengers generated in response to an enterotoxin exposure have been shown to activate CFTR and thus Cl " secretion.
- CFTR CFTR protein kinase C
- inflammatory mediators such as tumor necrosis factor- ⁇ and interleukin 1 and 8
- prostaglandins that are known metabolites of arachidonic acid (such as PGE 2 ).
- PGE 2 arachidonic acid
- ABC proteins such as MRP1 (ABCC1), MRP5 (ABCC5), and BCRP/MXR/ABCP (ABCG2).
- MRP1 ABCC1
- MRP5 ABCC5
- BCRP/MXR/ABCP ABCG2
- irinotecan has been shown to be a substrate of P-gp (ABCB1), MRP1 (ABCC1), MRP2 (ABCC2), and BCRP/MXR/ABCP (ABCG2). It is likely that interactions may occur between drugs and with other ABC proteins that are responsible for critical physiological functions.
- Irinotecan [l,4'-Bipiperidine]-r-carboxylic acid (4S)-4,l l-diethyl-3,4,12,14-tetrahydro- 4-hydroxy-3,14-dioxo-lH-pyrano[3',4':6,7]indolizino[l,2-t3]quinolin-9-yl ester is a camptothecin analog and topoisomerase-I inhibitor derived from a compound, which occurs naturally in the Chinese tree, Camptotheca acuminata.
- Irinotecan can be prepared following the procedure disclosed in U.S. Pat. No. 4,604,463, European patent No. 835,257 or S. Sawada et al, Chem.
- Irinotecan hydrochloride clinically investigated as CPT-11, is a commercially available compound (CAMPTOSARTM , Pharmacia Corp.).
- irinotecan encompasses all pharmaceutically acceptable salts of irinotecan, particularly the hydrochloride salt.
- irinotecan is irinotecan hydrochloride, namely CPT-11.
- Irinotecan is a prodrug extensively metabolized in the liver to various metabolites. It is cleaved enzymatically by carboxylesterases to form 7-ethyl-lO-hydroxycamptothecin (SN-38), which has cytotoxic activity that is 100 to 1,000 times greater than that of the parent drug.
- SN-38 is further conjugated to an inactive glucuronide (SN-38G) by uridine diphosphate glucuronosyltransferases.
- CPT-11 metabolites identified are the major plasma metabolite 7-ethyl-10-[4-N-(5-aminopentanoic acid)-l-piperidino]- carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-amino-l-piperidino]- carbonyloxycamptothecin ( ⁇ PC), resulting from a ring-opening oxidation of the terminal piperidine ring of CPT-11 mediated by cytochrome P450 3A4 enzymes.
- the major dose- limiting nonhematologic toxicity of irinotecan is diarrhea.
- camptothecin derivatives especially irinotecan and its active metabolite SN-38 would produce disturbances in colonic electrolyte transport by interacting with CFTR (ABCC7) in the colonic crypts, so contributing to diarrhea associated with the administration of said drug in a manner analogue to EID.
- CFTR CFTR
- the effect of said substances on Cl " conductance in CFTR (ABCC7)- transfected Xenopus laevis oocytes is evaluated via single voltage clamp conditions.
- chemotherapeutic agent includes diarrheagenic chemotherapeutic agents, i.e. chemotherapeutic agents which may potentially induce diarrhea when administered to a patient in need thereof such as, for example, fluoropyrimidines, e.g. 5-fluorouracil (5-FU), platinum derivatives, e.g. cisplatin and oxaliplatin, thymidylate synthase inhibitors e.g. raltitrexed and camptothecin derivatives, e.g. irinotecan, SN-38, rubitecan and topotecan.
- Preferred examples of diarrheagenic chemotherapeutic agents according to the invention are camptothecin derivatives, particularly irinotecan, SN-38 and topotecan.
- CFTR inhibitor includes small molecules such as glyburide (glibenclamide), thiazolidinones such as for example 3-[(3- trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone, flavinoids and/or monoclonal or polyclonal antibodies directed toward some part of CFTR (ABCC7).
- glyburide glibenclamide
- thiazolidinones such as for example 3-[(3- trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone
- flavinoids and/or monoclonal or polyclonal antibodies directed toward some part of CFTR (ABCC7).
- the present invention provides a method for treating diarrhea which results from the interaction of a camptothecin derivative, particularly selected from the group consisting of irinotecan, SN-38 and topotecan, with a CFTR protein, which comprises administering sequentially, separately or simultaneously with said chemotherapeutic agent a therapeutically effective amount of a CFTR protein inhibitor to a patient in need of the treatment of such a diarrhea.
- a camptothecin derivative particularly selected from the group consisting of irinotecan, SN-38 and topotecan
- the present invention provides a method for treating diarrhea which results from the interaction of irinotecan or SN-38, with a CFTR protein, which comprises administering sequentially, separately or simultaneously with said chemotherapeutic agent a therapeutically effective amount of a CFTR protein inhibitor to a patient in need of the treatment of such a diarrhea.
- treating includes, unless otherwise specified, preventing, controlling, ameliorating, alleviating, decreasing, reducing and inhibiting.
- the efficacy of a CFTR inhibitor for the treatment of diarrhea induced by the administration of a chemotherapeutic agent, such as for example irinotecan or SN-38, may be evaluated in CFTR knockout mice.
- the subject CFTR inhibitor would be found to be effective in the treatment of diarrhea induced by the administration of the selected diarrheagenic chemotherapeutic agent.
- Standardized methods for assessing diarrhea in cancer patients are needed to better manage CID.
- the initial assessment and management of CID should include an initial comprehensive and accurate clinical assessment, subsequent targeted reassessment, and the administration of appropriate pharmacological therapies at the optimal time and dosages. Since diarrhea can unbalance chloride levels in a patients undergoing diarrheagenic chemotherapy, monitoring alteration of chloride levels, for example by detecting chloride levels pre- and post- administration of the chemotherapeutic agent may help the physician to evaluate/predict the patient sensitivity to said diarrheagenic chemotherapeutic agents and hence optimizing time and dosages of the same.
- Chloride levels can be monitored, for example, through the detection of chloride in a sweat sample of the patient.
- Detection of chloride levels in a biological sample of a patient may be obtained, for example, by detecting chloride in a sweat sample of the patient, following a procedure known in the art.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a method for treating diarrhea caused by the interaction of a chemotherapeutic agent with a CFTR protein, which comprises administering sequentially, separately or simultaneously with said chemotherapeutic agent a therapeutically effective amount of a CFTR protein inhibitor to a patient in need of the treatment of such a diarrhea and a method for optimizing time and dosages of a diarrheagenic chemotherapeutic agent in a patient in need thereof, which comprises evaluating the sensitivity of said patients towards said agent through the detection of chloride levels in a biological sample of said patient and selecting a time and dosages of said agent based on the above chloride levels.
Description
Title SE OF CFTR INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED DIARRHEA
Field of the invention The present invention relates to the treatment of diarrhea induced by pharmacologically active agents, in particular chemotherapeutic agents.
Description of the invention
Chemotherapy-induced diarrhea (CID) is a prevalent and severe toxicity associated with a variety of sole agents and combinations chemotherapy regimens used for the treatment of cancer. Not only does the occurrence of diarrhea reduce the quality of life of cancer patients, it may also strongly impact the clinical decision about chemotherapy regimens so that patients may undergo changes in treatments. These changes include dose reductions, delays in administration of subsequent drug cycles, and a total discontinuation of therapy. Acute or persistent diarrhea can often increase the cost of care when conventional treatment is unsuccessful and hospitalization is required. Some chemotherapeutic drugs are more likely than others to cause diarrhea. Cisplatin and 5-fluorouracil, when administered alone, commonly cause diarrhea, as does irinotecan. About 8% of patients receiving 5-fluorouracil alone have severe or life-threatening diarrhea; the frequency increases to up to 25% when 5-fluorouracil is combined with leucovorin. Irinotecan causes severe diarrhea that may be life threatening. Irinotecan- induced diarrhea typically occurs 2 to 14 days after therapy. Several Phase II clinical studies report incidences of delayed CID as high as 80% with irinotecan and more than 18% of patients treated with CPT-11 required hospitalization because of diarrhea occurring alone or in combination with other gastrointestinal disturbances.
Although marked progress has been accomplished these last years, standardized and universally accepted methods for management of CID have not been developed. As a matter of fact, management of CID still represents a formidable challenge to the healthcare team and a substantial degree of further improvement is needed to ameliorate the effectiveness of specific treatments.
According to Kornblau et al. (J. of Pain and Symptom Management, Vol. 19, No. 2, Feb. 2000, pp 1 18-129), many factors contribute to diarrhea in the cancer patient, including damage to and maturational arrest of intestinal epithelium, inflammation, infection, and antibiotics. Although the pathophysiologic mechanisms for CID are not completely known, histopathologic evidence indicates that diarrhea is probably a multifactorial process that results in absorptive and secretory imbalance in the small bowel. Pathophysiologic mechanisms for cancer treatment-related diarrhea differ based on the causative factor.
According to Ippoliti (Am. J. of Health-System Pharm., Vol. 55(15), August 1, 1998, pp 1573-1580), diarrhea can be classified as osmotic, secretory, exudative, postresection, and motor. Osmotic diarrhea results from the ingestion of poorly absorbed substances that retard fluid absorption.
Both postresection and exudative diarrheas result from loss of functional intestinal mucosa: in exudative diarrhea, the mucosa is damaged by disease; in postresection diarrhea, some amount of functional mucosa is surgically removed.
Abnormally rapid transit time (causing reduced exposure of luminal contents to the intestinal wall) can result in motor diarrhea.
Inhibition of mucosal absorption or stimulation of secretion of fluid and electrolytes results in secretory diarrhea. Within the intestine, immature crypt cells secrete fluid into the lumen, and villi cells absorb fluid from the lumen. Secretory diarrhea can occur when either of these processes is disrupted and there is a net flow of fluid into the lumen. Movement of fluid across the crypt and villi cells is controlled chiefly by membrane- associated proteins involved in epithelial ion transport and smooth muscle contraction. These proteins, in turn, are regulated by secondary messengers, including cyclic nucleotides, elements of the phosphoinositide-diacylglycerol pathway, and free intracellular calcium.
Several studies suggest that cystic fibrosis transmembrane conductance regulator (CFTR), a member of the ATP-binding Cassette (ABC), subfamily C member 7 (ABCC7) is the final common pathway for intestinal chloride (Cl") and thus fluid secretion into the lumen of the small and large intestine. Activation of CFTR (ABCC7) by pathogenic microorganisms is a major factor in enterotoxin-induced diarrhea (EID)
produced by many gut pathogens. In many examples, second messengers generated in response to an enterotoxin exposure have been shown to activate CFTR and thus Cl" secretion. These second messengers include cAMP and cGMP protein kinase C, inflammatory mediators (such as tumor necrosis factor-α and interleukin 1 and 8), as well as prostaglandins that are known metabolites of arachidonic acid (such as PGE2). Despite the complex nature of events leading to ultimate effect of EID, the role of CFTR has been established using in-vitro studies and in mice where CFTR has been selectively deleted from the mouse. The interaction of chemotherapeutic agents with ABC transporters has been well established with the earliest research describing the role of ABCB1 also known as P- glycoprotein (P-gp) or multidrug resistance gene (MDR1) in the genesis of tumor drug resistance. Further research on acquired drug resistance in tumor cells identified other ABC proteins such as MRP1 (ABCC1), MRP5 (ABCC5), and BCRP/MXR/ABCP (ABCG2). Through the utilization of acquired drug resistance and through the expression of individual clones for these ABC transporters, prototypical substrates have been identified. However, it is important to recognize that there is much overlap in the ability of ABC transporters to interact with drugs or model investigative compounds. For instance, irinotecan has been shown to be a substrate of P-gp (ABCB1), MRP1 (ABCC1), MRP2 (ABCC2), and BCRP/MXR/ABCP (ABCG2). It is likely that interactions may occur between drugs and with other ABC proteins that are responsible for critical physiological functions.
Irinotecan [l,4'-Bipiperidine]-r-carboxylic acid (4S)-4,l l-diethyl-3,4,12,14-tetrahydro- 4-hydroxy-3,14-dioxo-lH-pyrano[3',4':6,7]indolizino[l,2-t3]quinolin-9-yl ester is a camptothecin analog and topoisomerase-I inhibitor derived from a compound, which occurs naturally in the Chinese tree, Camptotheca acuminata. Irinotecan can be prepared following the procedure disclosed in U.S. Pat. No. 4,604,463, European patent No. 835,257 or S. Sawada et al, Chem. Pharm. Bull. 39, 1446 (1991). Irinotecan hydrochloride, clinically investigated as CPT-11, is a commercially available compound (CAMPTOSAR™ , Pharmacia Corp.).
As used herein the term "irinotecan" encompasses all pharmaceutically acceptable salts of irinotecan, particularly the hydrochloride salt.
In a preferred aspect of the present invention, irinotecan is irinotecan hydrochloride, namely CPT-11. Irinotecan is a prodrug extensively metabolized in the liver to various metabolites. It is cleaved enzymatically by carboxylesterases to form 7-ethyl-lO-hydroxycamptothecin (SN-38), which has cytotoxic activity that is 100 to 1,000 times greater than that of the parent drug. SN-38 is further conjugated to an inactive glucuronide (SN-38G) by uridine diphosphate glucuronosyltransferases. Other CPT-11 metabolites identified are the major plasma metabolite 7-ethyl-10-[4-N-(5-aminopentanoic acid)-l-piperidino]- carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-amino-l-piperidino]- carbonyloxycamptothecin (ΝPC), resulting from a ring-opening oxidation of the terminal piperidine ring of CPT-11 mediated by cytochrome P450 3A4 enzymes. The major dose- limiting nonhematologic toxicity of irinotecan is diarrhea. Although the pharmacokinetic- pharmacodynamic relationship between exposure and toxicity has been widely studied, the results have been discrepant because of its complex and incompletely understood relationship and because of different study designs. Although most investigations have reported that area under the concentration-time curve (AUC) values for both irinotecan and SΝ-38 significantly correlated with the severity of diarrhea, others have detected that correlation only for irinotecan AUC. Similarly, although several studies have suggested that there is a correlation between the biliary index and diarrhea, other studies could not confirm that correlation. Finally, some trials failed to find any relationship between diarrhea and any of the studied pharmacokinetic parameters (Clinical Pharmacology and Therapeutics, Vol. 72(3), Sept. 2002, pp 265-275).
It has now been found that camptothecin derivatives, especially irinotecan and its active metabolite SN-38 would produce disturbances in colonic electrolyte transport by interacting with CFTR (ABCC7) in the colonic crypts, so contributing to diarrhea associated with the administration of said drug in a manner analogue to EID.
As an example, to determine the interaction of CPT-11, SN-38, and topotecan with CFTR (ABCC7), the effect of said substances on Cl" conductance in CFTR (ABCC7)- transfected Xenopus laevis oocytes is evaluated via single voltage clamp conditions.
It is therefore an object of the present invention a method for treating diarrhea caused by the interaction of a chemotherapeutic agent with a CFTR protein, which comprises administering sequentially, separately or simultaneously with said chemotherapeutic agent a therapeutically effective amount of a CFTR protein inhibitor to a patient in need of the treatment of such a diarrhea.
It is another object of the present invention a method for treating a cancer sensitive to a potential diarrheagenic chemotherapeutic agent, which comprises administering a therapeutically effective amount of a CFTR protein inhibitor for treating diarrhea occurring when said chemotherapeutic agent is administered to a patient.
According to the present invention the definition "chemotherapeutic agent" includes diarrheagenic chemotherapeutic agents, i.e. chemotherapeutic agents which may potentially induce diarrhea when administered to a patient in need thereof such as, for example, fluoropyrimidines, e.g. 5-fluorouracil (5-FU), platinum derivatives, e.g. cisplatin and oxaliplatin, thymidylate synthase inhibitors e.g. raltitrexed and camptothecin derivatives, e.g. irinotecan, SN-38, rubitecan and topotecan. Preferred examples of diarrheagenic chemotherapeutic agents according to the invention are camptothecin derivatives, particularly irinotecan, SN-38 and topotecan.
According to the present invention, the term "CFTR inhibitor" includes small molecules such as glyburide (glibenclamide), thiazolidinones such as for example 3-[(3- trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone, flavinoids and/or monoclonal or polyclonal antibodies directed toward some part of CFTR (ABCC7).
In a particular aspect, the present invention provides a method for treating diarrhea which results from the interaction of a camptothecin derivative, particularly selected from the group consisting of irinotecan, SN-38 and topotecan, with a CFTR protein, which comprises administering sequentially, separately or simultaneously with said chemotherapeutic agent a therapeutically effective amount of a CFTR protein inhibitor to a patient in need of the treatment of such a diarrhea.
In a more particular aspect, the present invention provides a method for treating diarrhea which results from the interaction of irinotecan or SN-38, with a CFTR protein, which comprises administering sequentially, separately or simultaneously with said chemotherapeutic agent a therapeutically effective amount of a CFTR protein inhibitor to a patient in need of the treatment of such a diarrhea.
According to the present invention the term "treating" includes, unless otherwise specified, preventing, controlling, ameliorating, alleviating, decreasing, reducing and inhibiting.
As an example, the efficacy of a CFTR inhibitor for the treatment of diarrhea induced by the administration of a chemotherapeutic agent, such as for example irinotecan or SN-38, may be evaluated in CFTR knockout mice.
It is believed that the subject CFTR inhibitor would be found to be effective in the treatment of diarrhea induced by the administration of the selected diarrheagenic chemotherapeutic agent.
Standardized methods for assessing diarrhea in cancer patients are needed to better manage CID. The initial assessment and management of CID should include an initial comprehensive and accurate clinical assessment, subsequent targeted reassessment, and the administration of appropriate pharmacological therapies at the optimal time and dosages.
Since diarrhea can unbalance chloride levels in a patients undergoing diarrheagenic chemotherapy, monitoring alteration of chloride levels, for example by detecting chloride levels pre- and post- administration of the chemotherapeutic agent may help the physician to evaluate/predict the patient sensitivity to said diarrheagenic chemotherapeutic agents and hence optimizing time and dosages of the same.
Chloride levels can be monitored, for example, through the detection of chloride in a sweat sample of the patient.
It is therefore another aspect of the present invention a method for assessing diarrhea in a cancer patient undergoing a diarrheagenic chemotherapy, which comprises monitoring chloride levels in said patient, in particular by detecting chloride levels pre- and post- administration of a chemotherapeutic agent.
It is a still another aspect of the present invention a method for optimizing time and dosages of a diarrheagenic chemotherapeutic agent in a patient in need thereof, which comprises evaluating the sensitivity of said patients towards said agent through the detection of chloride levels in a biological sample of said patient and selecting a time and dosages of said agent based on the above chloride levels.
Detection of chloride levels in a biological sample of a patient may be obtained, for example, by detecting chloride in a sweat sample of the patient, following a procedure known in the art.
It is a further another aspect of the present invention a method for optimizing the administration of a diarrheagenic chemotherapeutic agent, which comprises:
(a) obtaining a sweat sample before and subsequently the administration of said chemotherapeutic agent to a patient in need thereof;
(b) detecting the amount of chloride in said samples; and
(c ) selecting a therapeutically effective amount of said drug based on the above chloride levels.
further aspect of the present invention a method for treating a cancer sensitive agenic chemotherapeutic agent, which comprises:
(d) obtaining a sweat sample before and subsequently the administration of said chemotherapeutic agent to a patient in need thereof; (e) detecting the amount of chloride in said samples; and
(f) selecting a therapeutically effective amount of said drug based on the above chloride levels.
Claims
1. A method for treating diarrhea caused by the interaction of a diarrheagenic chemotherapeutic agent with a CFTR protein, which comprises administering sequentially, separately or simultaneously with said chemotherapeutic agent a therapeutically effective amount of a CFTR protein inhibitor to a patient in need of the treatment of such a diarrhea.
2. The method of claim 1, wherein the chemotherapeutic agent is selected from the group consisting of fluoropyrimidines, platinum derivatives, thymidylate synthase inhibitors and camptothecin derivatives.
3. The method of claim 2, wherein the camptothecin derivative is selected from the group consisting of irinotecan, SN-38, rubitecan and topotecan.
4. The method of claim 3 wherein the camptothecin derivative is irinotecan.
5. A method for treating a cancer sensitive to a potential diarrheagenic chemotherapeutic agent, which comprises administering a therapeutically effective amount of a CFTR protein inhibitor for treating diarrhea occurring when said chemotherapeutic agent is administered to a patient.
6. The method of claim 5, wherein the chemotherapeutic agent is selected from the group consisting of fluoropyrimidines, platinum derivatives, thymidylate synthase inhibitors and camptothecin derivatives.
7. The method of claim 6, wherein the camptothecin derivative is selected from the group consisting of irinotecan, SN-38, rubitecan and topotecan.
8. The method of claim 7 wherein the camptothecin derivative is irinotecan.
9. A method for assessing diarrhea in ?. cancer patient undergoing a diarrheagenic chemotherapy, which comprises monitoring chloride levels in said patient, in particular by detecting chloride levels pre- and post- administration of a chemotherapeutic agent.
10. A method for optimizing time and dosages of a diarrheagenic chemotherapeutic agent in a patient in need thereof, which comprises evaluating the sensitivity of said patients towards said agent through the detection of chloride levels in a biological sample of said patient and selecting a time and dosages of said agent based on the above chloride levels.
11. A method for optimizing the administration of a diarrheagenic chemotherapeutic agent, which comprises:
(a) obtaining a sweat sample before and subsequently the administration of said chemotherapeutic agent to a patient in need thereof;
(b) detecting the amount of chloride in said samples; and (c ) selecting a therapeutically effective amount of said drug based on the above chloride levels.
12. A method for treating a cancer sensitive to a diarrheagenic chemotherapeutic agent, which comprises: (d) obtaining a sweat sample before and subsequently the administration of said chemotherapeutic agent to a patient in need thereof;
(e) detecting the amount of chloride in said samples; and
(f) selecting a therapeutically effective amount of said drug based on the above chloride levels. '
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47234803P | 2003-05-21 | 2003-05-21 | |
| US60/472,348 | 2003-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004103371A1 true WO2004103371A1 (en) | 2004-12-02 |
Family
ID=33476943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2004/001660 Ceased WO2004103371A1 (en) | 2003-05-21 | 2004-05-14 | Use of cftr inhibitors for the treatment of chemotherapy-induced diarrhea |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20040235879A1 (en) |
| TW (1) | TW200507828A (en) |
| WO (1) | WO2004103371A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008121877A3 (en) * | 2007-04-02 | 2008-12-31 | Inst Oneworld Health | Cftr inhibitor compounds and uses thereof |
| US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2612309C (en) * | 2005-06-16 | 2014-12-16 | Mohammed Saeed | Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234922A (en) * | 1992-09-28 | 1993-08-10 | University Of Iowa Research Foundation | Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea |
| WO2001000217A1 (en) * | 1999-06-28 | 2001-01-04 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Medicinal compositions for preventing or treating diarrhea |
| WO2001049299A2 (en) * | 2000-01-06 | 2001-07-12 | Moore Malcolm J | Prevention of ironotecan induced diarrhea with activated carbon |
| WO2001052828A2 (en) * | 2000-01-18 | 2001-07-26 | University Of Massachusetts | Glutamine prevention of delayed-onset irinotecan-induced diarrhea |
| US6281240B1 (en) * | 1997-04-10 | 2001-08-28 | Eli Lilly And Company | Diarylsulfonylureas for use in treating secretory diarrhea |
| WO2002005794A2 (en) * | 2000-07-13 | 2002-01-24 | University Of Bristol | Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
-
2004
- 2004-05-14 WO PCT/IB2004/001660 patent/WO2004103371A1/en not_active Ceased
- 2004-05-20 TW TW093114277A patent/TW200507828A/en unknown
- 2004-05-20 US US10/850,070 patent/US20040235879A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234922A (en) * | 1992-09-28 | 1993-08-10 | University Of Iowa Research Foundation | Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea |
| US6281240B1 (en) * | 1997-04-10 | 2001-08-28 | Eli Lilly And Company | Diarylsulfonylureas for use in treating secretory diarrhea |
| WO2001000217A1 (en) * | 1999-06-28 | 2001-01-04 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Medicinal compositions for preventing or treating diarrhea |
| WO2001049299A2 (en) * | 2000-01-06 | 2001-07-12 | Moore Malcolm J | Prevention of ironotecan induced diarrhea with activated carbon |
| WO2001052828A2 (en) * | 2000-01-18 | 2001-07-26 | University Of Massachusetts | Glutamine prevention of delayed-onset irinotecan-induced diarrhea |
| WO2002005794A2 (en) * | 2000-07-13 | 2002-01-24 | University Of Bristol | Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
Non-Patent Citations (4)
| Title |
|---|
| ABIGERGES DANY ET AL: "Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 86, no. 6, 1994, pages 446 - 449, XP009035128, ISSN: 0027-8874 * |
| BLEIBERG H ET AL: "Characterisation and clinical management of CPT-11 (Irinotecan)-induced adverse events: The European perspective", EUROPEAN JOURNAL OF CANCER, vol. 32A, no. SUPPL. 3, 1996, pages S18 - S23, XP002291899, ISSN: 0959-8049 * |
| DATABASE PHAR [online] PJB PUBLICATIONS LTD.; 1995, "Tiorfan", XP002291900, retrieved from STN Database accession no. AN:4659 PHAR * |
| DATABASE WPI Section Ch Week 200112, Derwent World Patents Index; Class B03, AN 2001-112385, XP002291901 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008121877A3 (en) * | 2007-04-02 | 2008-12-31 | Inst Oneworld Health | Cftr inhibitor compounds and uses thereof |
| US8283351B2 (en) | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
| US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| US20040235879A1 (en) | 2004-11-25 |
| TW200507828A (en) | 2005-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhatt et al. | Recent advances in clinical development of leukotriene B4 pathway drugs | |
| US20200268768A1 (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| Barnes | Emerging pharmacotherapies for COPD | |
| Barnes | New therapies for chronic obstructive pulmonary disease | |
| US7928062B2 (en) | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) | |
| US8865641B2 (en) | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways | |
| BRPI0616344A2 (en) | Method for the treatment of chemical and behavioral dependence | |
| CN104981240A (en) | Compositions, methods and uses for the treatment of diabetes and related disorders by controlling blood sugar levels | |
| CA2832611C (en) | Methods for inhibiting allograft rejection | |
| CN106714809A (en) | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss | |
| JP2011525194A (en) | Composition for treating a fibrotic disease or condition | |
| TW202327589A (en) | Combination treatment of liver disorders | |
| US9539221B2 (en) | Method of treating airway diseases with β-adrenergic inverse agonists | |
| US20260102407A1 (en) | Treatment methods | |
| Möser et al. | Inhibition of the protein kinase IKKepsilon attenuates neuropathic pain in mice | |
| US20180344721A1 (en) | Medicinal Treatment of Chronic Inflammatory Dermal Disorders | |
| Géhin et al. | A novel CRTH2 antagonist: single‐and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects | |
| US20040235879A1 (en) | Method for treatment of chemotherapy-induced diarrhea | |
| WO2009080030A1 (en) | Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus | |
| JPH11501934A (en) | A composition comprising nicotinylalanine and an inhibitor of glycine conjugation or vitamin B6 | |
| JP2024528731A (en) | Ibudilast for preventing ocular cancer metastasis | |
| KR20110108355A (en) | How to cause cleavage of amyloid precursor protein so that new fragments are formed | |
| JPWO2017209270A1 (en) | A cell death inducer or cell death promoter selective for activated T cells and / or B cells, comprising 25-hydroxycholesterol or an analogue cholesterol thereof as an active ingredient | |
| CN120676946A (en) | DEBIO-0123 in combination with temozolomide and radiotherapy for the treatment of glioma | |
| CN115605198B (en) | Medications for treating fatty liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |